At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 408 enrolled
Drug / intervention
Vitamin D3 +1 moredrug
Likely dose
Vitamin D3 100,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma
In Brief
A Phase 3 clinical trial evaluating Vitamin D3 and Ciclesonide for Asthma. Completed, enrolled 408 participants across 16 sites.
Detailed Summary
The purpose of the study is to find out if taking vitamin D in addition to an asthma controller medication helps to prevent worsening of asthma symptoms and asthma attacks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartApr 2011
Primary CompletionJan 2014
TodayJul 2026
First PostedNov 25, 2010
Enrollment StartApr 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.6 years ago
Interventions
Vitamin D3drug
vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonidedrug
Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)